Volume 10, Issue 1 (January & February 2019)
BCN 2019, 10(1): 23-36 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jahanmahin A, Abbasnejad Z, Haghparast A, Ahmadiani A, Ghasemi R. The Effect of Intrahippocampal Insulin Injection on Scopolamine-induced Spatial Memory Impairment and Extracellular Signal-regulated Kinases Alteration. BCN 2019; 10 (1) :23-36
URL: http://bcn.iums.ac.ir/article-1-1096-en.html
URL: http://bcn.iums.ac.ir/article-1-1096-en.html
Ahmad Jahanmahin1 
, Zahra Abbasnejad1 , Abbas Haghparast1 , Abolhassan Ahmadiani1 , Rasoul Ghasemi * 2
, Zahra Abbasnejad1 , Abbas Haghparast1 , Abolhassan Ahmadiani1 , Rasoul Ghasemi * 2
1- Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neurophysiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neurophysiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Introduction: It is well documented that insulin has neuroprotective and neuromodulator effects and can protect against different models of memory loss. Furthermore, cholinergic activity plays a significant role in memory, and scopolamine-induced memory loss is widely used as an experimental model of dementia. The current study aimed at investigating the possible effects of insulin against scopolamine-induced memory impairment in Wistar rat and its underlying molecular mechanisms.
Methods: Accordingly, animals were bilaterally cannulated in CA1, hippocampus. Intrahippocampal administration of insulin 6 MU and 12 MU in CA1 per day was performed during first 6 days after surgery. During next four days, the animal’s spatial learning and memory were assessed in Morris water maze test (three days of learning and one day of retention test). The animals received scopolamine (1 mg/kg) Intraperitoneally (IP) 30 minutes before the onset of behavioral tests in each day. In the last day, the hippocampi were dissected and the levels of MAPK (mitogen-activated protein kinases) and caspase-3 activation were analyzed by Western blot technique.
Results: The behavioral results showed that scopolamine impaired spatial learning and memory without activating casapase-3, P38, and JNK, but chronic pretreatment by both doses of insulin was unable to restore this spatial memory impairment. In addition, scopolamine significantly reduced Extracellular signal-Regulated Kinases (ERKs) activity and insulin was unable to restore this reduction. Results revealed that scopolamine-mediated memory loss was not associated with hippocampal damage.
Conclusion: Insulin as a neuroprotective agent cannot restore memory when there is no hippocampal damage. In addition, the neuromodulator effect of insulin is not potent enough to overwhelm scopolamine-mediated disruptions of synaptic neurotransmission.
Methods: Accordingly, animals were bilaterally cannulated in CA1, hippocampus. Intrahippocampal administration of insulin 6 MU and 12 MU in CA1 per day was performed during first 6 days after surgery. During next four days, the animal’s spatial learning and memory were assessed in Morris water maze test (three days of learning and one day of retention test). The animals received scopolamine (1 mg/kg) Intraperitoneally (IP) 30 minutes before the onset of behavioral tests in each day. In the last day, the hippocampi were dissected and the levels of MAPK (mitogen-activated protein kinases) and caspase-3 activation were analyzed by Western blot technique.
Results: The behavioral results showed that scopolamine impaired spatial learning and memory without activating casapase-3, P38, and JNK, but chronic pretreatment by both doses of insulin was unable to restore this spatial memory impairment. In addition, scopolamine significantly reduced Extracellular signal-Regulated Kinases (ERKs) activity and insulin was unable to restore this reduction. Results revealed that scopolamine-mediated memory loss was not associated with hippocampal damage.
Conclusion: Insulin as a neuroprotective agent cannot restore memory when there is no hippocampal damage. In addition, the neuromodulator effect of insulin is not potent enough to overwhelm scopolamine-mediated disruptions of synaptic neurotransmission.
Keywords: Alzheimer Disease, Cholinergic neurons, Scopolamine, Mitogen-Activated Protein Kinases, Caspase-3, Apoptosis
Type of Study: Original |
Subject:
Behavioral Neuroscience
Received: 2017/12/19 | Accepted: 2018/03/6 | Published: 2019/01/1
Received: 2017/12/19 | Accepted: 2018/03/6 | Published: 2019/01/1
References
1. Sotiriadis C, Vo QD, Ciarpaglini R, et al. Cystic meningioma: diagnostic difficulties and utility of MRI in diagnosis and management. BMJ Case Rep. 2015;2015. [DOI:10.1136/bcr-2014-208274] [PMID] [PMCID]
2. Fortuna A, Ferrante L, Acqui M, et al. Cystic meningiomas. Acta Neurochirurgica. 1988;90(1):23-30. [DOI:10.1007/BF01541262] [PMID]
3. Go KO, Lee K, Heo W, et al. Cystic Meningiomas: Correlation between Radiologic and Histopathologic Features. Brain Tumor Res Treat. 2018;6(1):13-21. [DOI:10.14791/btrt.2018.6.e3] [PMID] [PMCID]
4. Guan TK, Pancharatnam D, Chandran H, et al. Infratentorial benign cystic meningioma mimicking a hemangioblastoma radiologically and a pilocytic astrocytoma intraoperatively: a case report. Journal of Medical Case Reports. 2013;7(1):87. [DOI:10.1186/1752-1947-7-87] [PMID] [PMCID]
5. Worthington C, Caron J-L, Melanson D, et al. Meningioma cysts. Neurology. 1985;35(12):1720. [DOI:10.1212/WNL.35.12.1720] [PMID]
6. Nakasu S, Hirano A, Shimura T, et al. Incidental meningiomas in autopsy study. Surg Neurol. 1987;27(4):319-322. [DOI:10.1016/0090-3019(87)90005-X]
7. Watts J, Box G, Galvin A, et al. Magnetic resonance imaging of meningiomas: a pictorial review. Insights Imaging. 2014;5(1):113-122. [DOI:10.1007/s13244-013-0302-4] [PMID] [PMCID]
8. Go KO, Lee K, Heo W, et al. Cystic Meningiomas: Correlation between Radiologic and Histopathologic Features. Brain tumor research and treatment. 2018;6(1):13-21. [DOI:10.14791/btrt.2018.6.e3] [PMID] [PMCID]
9. Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and misleading features in meningioma. Radiographics. 1991;11(6):1087-1106. [DOI:10.1148/radiographics.11.6.1749851] [PMID]
10. Maj B, Łatka D, Kita P. [Cystic meningioma: report of three cases]. Neurol Neurochir Pol. 2002;36(1):199-206.
11. Saxena D, Rout P, Pavan K, et al. MRI Findings Of An Atypical Cystic Meningioma-A Rare.
12. Jorge D, Nadia G, Claudio V, et al. Cystic meningioma simulating arachnoid cyst: report of an unusual case. Case reports in radiology. 2014;2014. [DOI:10.1155/2014/371969] [PMID] [PMCID]
13. Nauta HJ, Tucker WS, Horsey WJ, et al. Xanthochromic cysts associated with meningioma. J Neurol Neurosurg Psychiatry. 1979;42(6):529-535. [DOI:10.1136/jnnp.42.6.529] [PMID] [PMCID]
14. Ferrante L, Acqui M, Lunardi P, et al. MRI in the diagnosis of cystic meningiomas: Surgical implications. Acta Neurochirurgica. 1997;139(1):8-11. [DOI:10.1007/BF01850861] [PMID]
15. Mittal A, Layton KF, Finn SS, et al. Cystic meningioma: unusual imaging appearance of a common intracranial tumor. Proc (Bayl Univ Med Cent). 2010;23(4):429-431. [DOI:10.1080/08998280.2010.11928664] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
